Ex vivo expanded mobilized peripheral blood CD34+ cells accelerate haematological recovery in a baboon model of autologous transplantation

To address the value of ex vivo expanded haematopoietic cells for shortening cytopenia in autologous haematopoietic transplantation, we designed an ex vivo expansion protocol based on a cocktail of early acting cytokines and short‐term culture and tested it in a baboon model. Expansion involved enriched CD34+ peripheral blood haematopoietic cells cultured for 6 d with a combination of FLT3‐L, stem cell factor (SCF), thrombopoietin (TPO) and interleukin (IL)‐3 (50 ng/ml each); CD34+ cells, granulocyte–macrophage colony‐forming units (GM‐CFU) and megakaryocytic colony‐forming units (MK‐CFU) were amplified, respectively, 10·5‐, 20·5‐ and 17·9‐fold. Baboons were submitted to a myeloablative regimen consisting of cyclophosphamide plus total body irradiation (TBI; 6 Gy) and were then grafted with either 2 × 106/kg unmanipulated CD34+ cells (control group, n = 4) or cells cultured from 2 × 106/kg CD34+ cells (expansion group, n = 4). No cytokines were administered after transplantation. All the animals engrafted. The mean times to white blood cell (WBC), granulocyte and platelet recovery were significantly shorter in the expansion group than in the control group: WBC (> 1 × 109/l) and neutrophil (> 0·5 × 109/l) recovery occurred on days 8 (range 6–9) and 9 (range 6–11), respectively, compared with days 12 (range 10–15) and 14 (range 11–16); platelets recovered (> 20 × 109/l) on day 9 (range 7–12) compared with day 13 (range 11–15) in the control group (P < 0·05). No toxicity was observed after reinfusion. No secondary hypoplasia was observed during more than 12 months of follow‐up. Functions of both neutrophils and platelets produced from expanded cells were normal in terms of oxidative metabolism, chemotaxis and the bleeding time. This study shows that in comparison with unmanipulated cells peripheral blood haematopoietic cells expanded from similar doses of CD34+ cells, under the conditions defined here, accelerated both neutrophil and platelet recovery without impairing long‐term haematopoiesis.

[1]  J. Tisdale,et al.  Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. , 1998, Blood.

[2]  J. Wuu,et al.  The Fluctuating Phenotype of the Lymphohematopoietic Stem Cell with Cell Cycle Transit , 1998, The Journal of experimental medicine.

[3]  R. Willemze,et al.  The early phase of engraftment after murine blood cell transplantation is mediated by hematopoietic stem cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Cindy L. Miller,et al.  Expansion in vitro of adult murine hematopoietic stem cells with transplantable lympho-myeloid reconstituting ability. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  T. Soma,et al.  Murine long-term repopulating ability is compromised by ex vivo culture in serum-free medium despite preservation of committed progenitors. , 1997, Journal of hematotherapy.

[6]  J. Dick,et al.  Quantitative Analysis Reveals Expansion of Human Hematopoietic Repopulating Cells After Short-term Ex Vivo Culture , 1997, The Journal of experimental medicine.

[7]  E. Fitzsimons,et al.  CD34 positive PBPC expanded ex vivo may not provide durable engraftment following myeloablative chemoradiotherapy regimens , 1997, Bone Marrow Transplantation.

[8]  P. Pedrazzoli,et al.  Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. , 1997, Blood.

[9]  C. Hannum,et al.  FLT3 ligand preserves the ability of human CD34+ progenitors to sustain long-term hematopoiesis in immune-deficient mice after ex vivo retroviral-mediated transduction. , 1997, Blood.

[10]  H. Ramshaw,et al.  Increased recruitment of hematopoietic progenitor cells underlies the ex vivo expansion potential of FLT3 ligand. , 1997, Blood.

[11]  R. Hoffman,et al.  Partially differentiated ex vivo expanded cells accelerate hematologic recovery in myeloablated mice transplanted with highly enriched long-term repopulating stem cells. , 1996, Blood.

[12]  W M Miller,et al.  Hematopoietic cell culture therapies (Part II): Clinical aspects and applications. , 1996, Trends in biotechnology.

[13]  V. Broudy,et al.  The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. , 1996, Blood.

[14]  J M Piret,et al.  Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells: novel responses to Flt3-ligand and thrombopoietin , 1996, The Journal of experimental medicine.

[15]  D. Dunlop,et al.  CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Kaushansky,et al.  Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. , 1996, Blood.

[17]  S. Emerson,et al.  Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells: the next generation of cellular therapeutics. , 1996, Blood.

[18]  J G Bender,et al.  Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer. , 1996, Blood.

[19]  C. Eaves,et al.  Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Eaves,et al.  Characterization and purification of a primitive hematopoietic cell type in adult mouse marrow capable of lymphomyeloid differentiation in long-term marrow "switch" cultures. , 1995, Blood.

[21]  S. Heimfeld,et al.  Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. , 1995, The New England journal of medicine.

[22]  D. Brooks,et al.  Long-term repopulation of irradiated mice with limiting numbers of purified hematopoietic stem cells: in vivo expansion of stem cell phenotype but not function. , 1995, Blood.

[23]  I. Weissman,et al.  Rapid and sustained hematopoietic recovery in lethally irradiated mice transplanted with purified Thy-1.1lo Lin- Sca-1+ hematopoietic stem cells , 1994 .

[24]  K. Leibundgut,et al.  Evaluation of the Fresenius cell separator AS 104 for harvesting peripheral blood stem cells in pediatric patients. , 1994, Transfusion science.

[25]  C. Eaves,et al.  Amplification of Sca-1+ Lin-WGA+ cells in serum-free cultures containing steel factor, interleukin-6, and erythropoietin with maintenance of cells with long-term in vivo reconstituting potential , 1994 .

[26]  Connie,et al.  Amplification of Sca-1+ Lin- WGA+ cells in serum-free cultures containing steel factor, interleukin-6, and erythropoietin with maintenance of cells with long-term in vivo reconstituting potential. , 1994, Blood.

[27]  M. Moore,et al.  Bone marrow transplantation with interleukin-1 plus kit-ligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem cell lineage and proliferative potential , 1993 .

[28]  P. Lansdorp,et al.  Expression of Thy-1 on human hematopoietic progenitor cells , 1993, The Journal of experimental medicine.

[29]  M. Moore,et al.  Bone marrow transplantation with interleukin-1 plus kit-ligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem cell lineage and proliferative potential. , 1993, Blood.

[30]  L. To,et al.  Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. , 1992, Blood.

[31]  M. Moore.  Does stem cell exhaustion result from combining hematopoietic growth factors with chemotherapy? If so, how do we prevent it? , 1992, Blood.

[32]  R. M. Fox,et al.  Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy , 1992, The Lancet.

[33]  M. Kris,et al.  Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. , 1994, The New England journal of medicine.

[34]  M. Kris,et al.  Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer , 1991 .

[35]  J. Armitage,et al.  The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. , 1991, Blood.

[36]  G. Bonadonna,et al.  Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. , 1989, Blood.

[37]  R. Bast,et al.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. , 1988, The New England journal of medicine.

[38]  Ihor R. Lemischka,et al.  Developmental potential and dynamic behavior of hematopoietic stem cells , 1986, Cell.

[39]  G. Keller,et al.  Expression of a foreign gene in myeloid and lymphoid cells derived from multipotent haematopoietic precursors , 1985, Nature.

[40]  J. Dick,et al.  Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice , 1985, Cell.

[41]  M. Seeds,et al.  Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. , 1983, Journal of immunology.

[42]  W. Falk,et al.  Rapid quantitation of neutrophil chemotaxis: use of a polyvinylpyrrolidone-free polycarbonate membrane in a multiwell assembly. , 1980, Journal of immunological methods.